The partnership brings together Pfizer’s scientific data and therapeutic expertise with Boltz’s open-source AI foundation ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Drugmaker CEOs see sales online channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect ...

PFE's oncology results should reflect steady growth from Seagen ADCs and key brands, offset by pricing and competitive pressures.

Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to ...

Asthma and COPD Drugs Market is expected to reach US$ 82.2 Billion by 2036, driven by Advancements in Drug Discovery and ...

The "Cancer Antibody Drug Conjugates Global Market Report 2025" has been added to ResearchAndMarkets.com's offering.The ...

Madrigal Pharmaceuticals (MDGL) stock is in focus as the company licenses Pfizer’s (PFE) experimental MASH therapy ervogastat. Read more here.

Novo Nordisk's CEO spoke about GLP-1 pricing and Pfizer's CEO spoke about the company's obesity ambitions while at the ...

Tuesday, U.S. Senator Roger Marshall sent a letter to the DEA, urging it to classify 7-OH as an illegal substance.